{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:56:00Z","timestamp":1791428160010,"version":"4.3.3"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T00:00:00Z","timestamp":1586563200000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Joint Science\u00a0and Technology Office for Chemical and Biological Defense","award":["W81XWH-11-0294 A7"],"award-info":[{"award-number":["W81XWH-11-0294 A7"]}]},{"DOI":"10.13039\/100010201","name":"USAMRIID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010201","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Vaccines\/GlaxoSmithKline\u00a0Biologicals SA"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.ymthe.2018.12.013","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T22:35:50Z","timestamp":1546986950000},"page":"850-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":62,"title":["Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice"],"prefix":"10.1016","volume":"27","author":[{"given":"Marcelo M.","family":"Samsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley C.","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clayton W.","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Six","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie S.","family":"Schmaljohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Geall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey B.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2018.12.013_bib1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.micro.55.1.235","article-title":"Biological weapons\u2014a primer for microbiologists","volume":"55","author":"Hawley","year":"2001","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated\u00a0VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"issue":"Suppl 4","key":"10.1016\/j.ymthe.2018.12.013_bib3","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for Venezuelan equine encephalitis","volume":"27","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib4","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1016\/j.vaccine.2004.12.023","article-title":"Genetically engineered, live, attenuated vaccines protect nonhuman primates\u00a0against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis\u00a0virus","volume":"23","author":"Reed","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4269\/ajtmh.2001.64.49","article-title":"Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice","volume":"64","author":"Ludwig","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.ymthe.2018.12.013_bib6","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1016\/j.vaccine.2008.04.044","article-title":"Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates","volume":"26","author":"Fine","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib7","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2012.04.060","article-title":"RNA-based vaccines","volume":"30","author":"Ulmer","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib8","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2018.12.013_bib9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2018.12.013_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2018.12.013_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1146\/annurev.immunol.15.1.617","article-title":"DNA vaccines","volume":"15","author":"Donnelly","year":"1997","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/path.1874","article-title":"Rational design of gene-based vaccines","volume":"208","author":"Barouch","year":"2006","journal-title":"J.\u00a0Pathol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib13","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1146\/annurev.immunol.18.1.927","article-title":"DNA vaccines: immunology, application, and optimization*","volume":"18","author":"Gurunathan","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3527(00)55001-5","article-title":"DNA vaccines for viral infections: basic studies and applications","volume":"55","author":"Robinson","year":"2000","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.ymthe.2018.12.013_bib15","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2018.12.013_bib16","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.4049\/jimmunol.1601877","article-title":"Induction of an IFN-Mediated Antiviral Response by a Self-Amplifying RNA Vaccine: Implications for Vaccine Design","volume":"198","author":"Pepini","year":"2017","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib17","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4161\/rna.27717","article-title":"Toward a crystal-clear view of the viral RNA sensing and response by RIG-I-like receptors","volume":"11","author":"Luo","year":"2014","journal-title":"RNA Biol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib18","doi-asserted-by":"crossref","first-page":"8147","DOI":"10.1128\/JVI.00733-12","article-title":"New PARP gene with an anti-alphavirus function","volume":"86","author":"Atasheva","year":"2012","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/rmv.633","article-title":"Recognition of viral nucleic acids in innate immunity","volume":"20","author":"Yoneyama","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib20","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14760584.2015.965690","article-title":"Self-replicating alphavirus RNA vaccines","volume":"14","author":"Ljungberg","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2018.12.013_bib22","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation RNA vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.12.013_bib23","first-page":"20","article-title":"Using self-amplifying mRNA vaccines to facilitate a rapid response to pandemic influenza","volume":"19","author":"Geall","year":"2014","journal-title":"European Pharmaceutical Review"},{"key":"10.1016\/j.ymthe.2018.12.013_bib24","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1038\/emi.2013.54","article-title":"Rapidly produced SAM(\u00ae) vaccine against H7N9 influenza is immunogenic in mice","volume":"2","author":"Hekele","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.ymthe.2018.12.013_bib25","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41467-018-05041-7","article-title":"Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection","volume":"9","author":"Baeza Garcia","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2018.12.013_bib26","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in\u00a0rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.ymthe.2018.12.013_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin","volume":"90","author":"Brazzoli","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59(\u00ae) adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O\u2019Hagan","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2018.12.013_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2217\/fmb.09.59","article-title":"A structural and functional perspective of alphavirus replication and assembly","volume":"4","author":"Jose","year":"2009","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib30","doi-asserted-by":"crossref","first-page":"12077","DOI":"10.1128\/JVI.01406-14","article-title":"Combined alphavirus replicon particle\u00a0vaccine induces durable and cross-protective immune responses against equine encephalitis viruses","volume":"88","author":"Reed","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib31","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1128\/JVI.02881-12","article-title":"Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus\u00a0attenuation","volume":"87","author":"Atasheva","year":"2013","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1743-422X-6-118","article-title":"Improved efficacy\u00a0of a gene optimised adenovirus-based vaccine for venezuelan equine encephalitis virus","volume":"6","author":"Williams","year":"2009","journal-title":"Virol. J."},{"key":"10.1016\/j.ymthe.2018.12.013_bib33","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/CVI.00030-11","article-title":"A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates","volume":"18","author":"Dupuy","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib34","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.vaccine.2004.06.056","article-title":"Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus","volume":"23","author":"Phillpotts","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib35","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S0264-410X(01)00505-9","article-title":"Monoclonal antibody protects mice against infection and disease when given either before or up to 24\u00a0h after airborne challenge with virulent Venezuelan equine encephalitis virus","volume":"20","author":"Phillpotts","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.virol.2007.05.041","article-title":"Alpha-beta T\u00a0cells provide protection against lethal encephalitis in the murine model of VEEV infection","volume":"367","author":"Paessler","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2018.12.013_bib37","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2009.04.015","article-title":"CD4+ T\u00a0cells provide protection against acute lethal encephalitis caused by Venezuelan equine encephalitis virus","volume":"27","author":"Yun","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib38","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/S0264-410X(03)00362-1","article-title":"Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus\u00a0and Venezuelan equine encephalitis virus","volume":"21","author":"Riemenschneider","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib39","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.vaccine.2016.04.077","article-title":"A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation","volume":"34","author":"Hannaman","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.vaccine.2016.11.040","article-title":"Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens","volume":"35","author":"Maruggi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2018.12.013_bib42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300985817738095","article-title":"Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey","volume":"55","author":"Sedic","year":"2018","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines","volume":"16","author":"Iavarone","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ymthe.2018.12.013_bib44","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jmv.10086","article-title":"Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus","volume":"67","author":"Elvin","year":"2002","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib45","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.4049\/jimmunol.129.6.2763","article-title":"Determination of the protective epitopes on the glycoproteins of Venezuelan equine encephalomyelitis virus by passive transfer of monoclonal antibodies","volume":"129","author":"Mathews","year":"1982","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0042-6822(85)90343-5","article-title":"The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes","volume":"142","author":"Roehrig","year":"1985","journal-title":"Virology"},{"key":"10.1016\/j.ymthe.2018.12.013_bib47","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0264-410X(95)93315-Z","article-title":"Localization of a protective epitope on a Venezuelan equine encephalomyelitis (VEE) virus peptide that protects mice from both epizootic and enzootic VEE virus challenge and is immunogenic in horses","volume":"13","author":"Hunt","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib48","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1099\/vir.0.81925-0","article-title":"A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus","volume":"87","author":"Hunt","year":"2006","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0264-410X(00)00123-7","article-title":"An immunological profile of Balb\/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine","volume":"19","author":"Bennett","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/297070a0","article-title":"Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis","volume":"297","author":"Schmaljohn","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2018.12.013_bib51","doi-asserted-by":"crossref","first-page":"12683","DOI":"10.1128\/JVI.01345-10","article-title":"Antibody to the E3 glycoprotein protects mice against lethal venezuelan equine encephalitis virus infection","volume":"84","author":"Parker","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib52","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/jvi.55.3.594-600.1985","article-title":"Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies","volume":"55","author":"Mathews","year":"1985","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib53","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1099\/vir.0.038281-0","article-title":"Early activation of the host complement system is required to restrict central nervous system invasion and limit neuropathology during Venezuelan equine encephalitis virus\u00a0infection","volume":"93","author":"Brooke","year":"2012","journal-title":"J.\u00a0Gen. Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib54","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0168-1702(02)00275-7","article-title":"Cytotoxic T-cell activity is not detectable in Venezuelan equine encephalitis virus-infected mice","volume":"91","author":"Jones","year":"2003","journal-title":"Virus Res."},{"key":"10.1016\/j.ymthe.2018.12.013_bib55","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1128\/JVI.02545-09","article-title":"T\u00a0cells facilitate recovery from Venezuelan equine encephalitis virus-induced encephalomyelitis in the absence of antibody","volume":"84","author":"Brooke","year":"2010","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2018.12.013_bib56","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/4031","article-title":"In\u00a0vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model","volume":"4","author":"Mandl","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2018.12.013_bib57","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.vaccine.2012.12.050","article-title":"Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine","volume":"31","author":"Tretyakova","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.vaccine.2012.12.009","article-title":"Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies","volume":"31","author":"Loomis","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib59","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0264-410X(98)00335-1","article-title":"Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors","volume":"17","author":"Hodgson","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0264-410X(96)00204-6","article-title":"Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB\/c, but not C3H\/HeN mice","volume":"15","author":"Hart","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.ymthe.2018.12.013_bib61","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0264-410X(97)00192-8","article-title":"Use of telemetry to\u00a0assess vaccine-induced protection against parenteral and aerosol infections of\u00a0Venezuelan equine encephalitis virus in non-human primates","volume":"16","author":"Pratt","year":"1998","journal-title":"Vaccine"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619300012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619300012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:56:11Z","timestamp":1761501371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619300012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1525001619300012"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.013","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2018.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}